Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a ...

RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:25 results, ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in ...

Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

A faculty member with the University of Wyoming’s Fay W. Whitney School of Nursing has been featured in the summer 2025 ...